Clinuvel Pharmaceuticals Limited (AU:CUV)
ASX:CUV
CUV Stock Chart & Stats
AU$11.08
-AU$0.31(-2.63%)
At close: 4:00 PM EST
AU$11.08
-AU$0.31(-2.63%)
Day’s Range― - ―
52-Week RangeAU$8.97 - AU$14.00
Previous CloseN/A
Volume193.84K
Average Volume (3M)97.23K
Market Cap
AU$452.31M
Enterprise ValueAU$423.38M
Total Cash (Recent Filing)AU$233.00M
Total Debt (Recent Filing)AU$341.09K
Price to Earnings (P/E)15.0
Beta0.63
Next Earnings
Sep 01, 2026EPS Estimate
0.52Next Dividend Ex-DateN/A
Dividend Yield0.38%
Share Statistics
EPS (TTM)0.21
Shares Outstanding50,200,740
10 Day Avg. Volume118,433
30 Day Avg. Volume97,231
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.16
Price to Sales (P/S)5.47
P/FCF Ratio12.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$20.80Price Target Upside87.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.71
Revenue Forecast (FY)AU$99.25M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetA large cash position and two decades operating without debt give durable financial flexibility. Low leverage reduces refinancing and solvency risk, enabling self-funding of clinical programs, manufacturing scale-up and commercial expansion without reliance on dilutive or costly external financing.
Sustained ProfitabilityConsistent profitability across multiple periods demonstrates resilient unit economics and disciplined commercial execution. Profitability supports reinvestment into R&D and operations, lowers financing needs and signals that the core business model can generate free cash across business cycles.
Improving Market Access And ScaleRegulatory and commercial progress—expanded dosing allowance and broadening site coverage—structurally increase addressable usage and distribution capacity. These changes underpin sustainable volume growth and higher utilization of SCENESSE across approved markets over the medium term.
Bears Say
Rising Operating ExpensesMaterial expense growth—personnel, commercial distribution and R&D consumables—raises structural operating leverage. If revenue growth remains modest, sustained expense escalation can compress margins, increase cash burn volatility and reduce the pace at which investments translate into profitable scale.
Regulatory & Timing RiskSequential trial completion requirements and pending SEC/ADR feedback create durable timing uncertainty for key filings and market expansions. Delays in approvals or listings will postpone potential new‑indication revenues and heighten execution risk for the company's diversification strategy.
Single‑product ConcentrationRevenue dependence on one product concentrates commercial and reimbursement risk. Long‑term growth and resilience hinge on SCENESSE uptake, payer decisions and site access; any competitive, reimbursement or supply disruption could materially affect company cash flows and strategic flexibility.
Clinuvel Pharmaceuticals News
CUV FAQ
What was Clinuvel Pharmaceuticals Limited’s price range in the past 12 months?
Clinuvel Pharmaceuticals Limited lowest share price was AU$8.97 and its highest was AU$14.00 in the past 12 months.
What is Clinuvel Pharmaceuticals Limited’s market cap?
Clinuvel Pharmaceuticals Limited’s market cap is AU$452.31M.
When is Clinuvel Pharmaceuticals Limited’s upcoming earnings report date?
Clinuvel Pharmaceuticals Limited’s upcoming earnings report date is Sep 01, 2026 which is in 146 days.
How were Clinuvel Pharmaceuticals Limited’s earnings last quarter?
Clinuvel Pharmaceuticals Limited released its earnings results on Feb 25, 2026. The company reported AU$0.206 earnings per share for the quarter, missing the consensus estimate of AU$0.293 by -AU$0.087.
Is Clinuvel Pharmaceuticals Limited overvalued?
According to Wall Street analysts Clinuvel Pharmaceuticals Limited’s price is currently Undervalued.
Does Clinuvel Pharmaceuticals Limited pay dividends?
Clinuvel Pharmaceuticals Limited pays a Annually dividend of AU$0.05 which represents an annual dividend yield of 0.38%. See more information on Clinuvel Pharmaceuticals Limited dividends here
What is Clinuvel Pharmaceuticals Limited’s EPS estimate?
Clinuvel Pharmaceuticals Limited’s EPS estimate is 0.52.
How many shares outstanding does Clinuvel Pharmaceuticals Limited have?
Clinuvel Pharmaceuticals Limited has 50,200,740 shares outstanding.
What happened to Clinuvel Pharmaceuticals Limited’s price movement after its last earnings report?
Clinuvel Pharmaceuticals Limited reported an EPS of AU$0.206 in its last earnings report, missing expectations of AU$0.293. Following the earnings report the stock price went down -3.243%.
Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in AU:CUV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clinuvel Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$20.80 (87.70% Upside)
AU$20.80 (87.70% Upside)
Blogger Sentiment
Bullish
AU:CUV Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.09%
12-Months-Change
Fundamentals
Return on Equity
13.29%
Trailing 12-Months
Asset Growth
22.98%
Trailing 12-Months
Company Description
Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with severe skin disorders and other related conditions. The company operates primarily in the healthcare sector, with a strong emphasis on photoprotection and skin repair. Its flagship product, SCENESSE (afamelanotide), is designed to provide protection against the harmful effects of ultraviolet (UV) light and is particularly beneficial for individuals with erythropoietic protoporphyria (EPP), a rare genetic disease that causes extreme sensitivity to sunlight.
CUV Company Deck
CUV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a generally positive outlook driven by modest revenue growth, record first-half sales, strong cash reserves and sustained profitability while management deliberately invests in in-house R&D, clinical and manufacturing capabilities. Those positives are tempered by materially higher operating expenses across personnel, R&D and corporate areas, a non-cash FX translation loss, and timing/uncertainty around regulatory filings (CUV107 completion required before submission) and the NASDAQ ADR uplift. On balance, the company emphasizes that expense increases are strategic investments supported by a strong balance sheet and cash runway.View all AU:CUV earnings summariesCUV Stock 12 Month Forecast
Average Price Target
AU$20.80
▲(87.70% Upside)
Technical Analysis
Acrux
―
Starpharma Holdings Limited
―
PYC Therapeutics Limited
―
Botanix Pharmaceuticals Limited
―
Biome Australia Ltd
―
Options Prices
Currently, No data available
---